<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>339</serviceExecutionTime><Drug id="84242"><DrugName>insulin lispro protamine suspension biosimilar, Gan &amp; Lee Pharmaceuticals</DrugName><DrugNamesKey><Name id="43050590">Suxiulin25</Name><Name id="42755223">insulin lispro</Name></DrugNamesKey><DrugSynonyms><Name><Value>insulin lispro</Value><Types><Type>INN</Type></Types></Name><Name><Value>protamine/zinc/insulin lispro (sc, diabetes), Gan &amp; Lee Pharmaceuticals</Value></Name><Name><Value>insulin lispro protamine suspension biosimilar, Gan &amp; Lee Pharmaceuticals</Value></Name><Name><Value>Suxiulin25</Value><Types><Type>Trade Name</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1071507">Gan &amp; Lee Pharmaceuticals</CompanyOriginator><CompaniesPrimary><Company id="1071507">Gan &amp; Lee Pharmaceuticals</Company></CompaniesPrimary><CrossReferences><SourceEntity id="1071507" type="Company"><TargetEntity id="5000745370" type="organizationId">Gan &amp; Lee Pharmaceuticals</TargetEntity></SourceEntity><SourceEntity id="97" type="ciIndication"><TargetEntity id="10012601" type="MEDDRA"/><TargetEntity id="D003920" type="MeSH"/><TargetEntity id="-203480060" type="omicsDisease"/><TargetEntity id="506" type="siCondition"/></SourceEntity><SourceEntity id="399" type="Action"><TargetEntity id="884" type="Mechanism">Glucose Lowering Agents</TargetEntity></SourceEntity><SourceEntity id="400" type="Action"><TargetEntity id="609" type="Mechanism">Insulin Secretagogues</TargetEntity><TargetEntity id="1034" type="Mechanism">Insulin Receptor Agonists</TargetEntity></SourceEntity><SourceEntity id="PTGT-04991" type="ciTarget"><TargetEntity id="129209803836303" type="siTarget">Insulin</TargetEntity><TargetEntity id="1003" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Diabetes mellitus - China - Nov-2014</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="97">Diabetes mellitus</Indication></IndicationsPrimary><ActionsPrimary><Action id="23014">Insulin ligand</Action><Action id="400">Insulin receptor agonist</Action></ActionsPrimary><ActionsSecondary><Action id="38212">Human insulin intermediate acting product</Action><Action id="399">Hypoglycemic agent</Action></ActionsSecondary><Technologies><Technology id="80">Peptide</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="647">Subcutaneous formulation</Technology><Technology id="962">Biosimilar product</Technology></Technologies><EphmraCodes><Ephmra><Code>A10C2</Code><Name>Human insulins and analogues, intermediate-acting</Name></Ephmra><Ephmra><Code>A10</Code><Name>DRUGS USED IN DIABETES</Name></Ephmra><Ephmra><Code>A10C</Code><Name>HUMAN INSULINS AND ANALOGUES</Name></Ephmra></EphmraCodes><LastModificationDate>2015-06-09T05:53:02.000Z</LastModificationDate><ChangeDateLast>2014-04-09T00:00:00.000Z</ChangeDateLast><AddedDate>2013-04-11T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1071507" linkType="Company"&gt;Gan &amp;amp; Lee Pharmaceuticals&lt;/ulink&gt;  has developed and launched  Suxiulin25,  a biosimilar version of &lt;ulink linkID="3353" linkType="Drug"&gt;insulin lispro protamine suspension&lt;/ulink&gt; (insulin lispro   25% + protamine zinc recombinant human insulin lispro 75%),  an intermediate acting formulation  of the rapid-acting  injectable human insulin analog   insulin lispro,  for the subcutaneous treatment of diabetes [&lt;ulink linkID="1342685" linkType="Reference"&gt;1342685&lt;/ulink&gt;], [&lt;ulink linkID="1627395" linkType="Reference"&gt;1627395&lt;/ulink&gt;]. In November 2014, the product was launched in China [&lt;ulink linkID="1627394" linkType="Reference"&gt;1627394&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In May 2011, the drug was  filed  for approval in China [&lt;ulink linkID="1342685" linkType="Reference"&gt;1342685&lt;/ulink&gt;]; in June 2012, supplemental material was requested to conclude the review  [&lt;ulink linkID="1398024" linkType="Reference"&gt;1398024&lt;/ulink&gt;]. In May 2014, it was approved as a class 6 therapeutic biologic in China [&lt;ulink linkID="1627392" linkType="Reference"&gt;1627392&lt;/ulink&gt;]. In November 2014, the product was launched  [&lt;ulink linkID="1627394" linkType="Reference"&gt;1627394&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1071507">Gan &amp; Lee Pharmaceuticals</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="97">Diabetes mellitus</Indication><StatusDate>2014-11-06T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1071507">Gan &amp; Lee Pharmaceuticals</Company><Country id="CN">China</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="97">Diabetes mellitus</Indication><StatusDate>2011-05-16T00:00:00.000Z</StatusDate><Source id="1342685" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1071507">Gan &amp; Lee Pharmaceuticals</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="97">Diabetes mellitus</Indication><StatusDate>2014-05-16T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01028"><Name>Insulin receptor</Name><SwissprotNumbers><Swissprot>P06213</Swissprot><Swissprot>P09208</Swissprot><Swissprot>P15127</Swissprot><Swissprot>P15208</Swissprot><Swissprot>Q28516</Swissprot><Swissprot>Q93105</Swissprot></SwissprotNumbers></Target><Target id="PTGT-04991"><Name>Insulin ligand</Name><SwissprotNumbers><Swissprot>O73727</Swissprot><Swissprot>P01308</Swissprot><Swissprot>P01310</Swissprot><Swissprot>P01311</Swissprot><Swissprot>P01313</Swissprot><Swissprot>P01314</Swissprot><Swissprot>P01315</Swissprot><Swissprot>P01316</Swissprot><Swissprot>P01317</Swissprot><Swissprot>P01318</Swissprot><Swissprot>P01319</Swissprot><Swissprot>P01320</Swissprot><Swissprot>P01321</Swissprot><Swissprot>P01324</Swissprot><Swissprot>P01327</Swissprot><Swissprot>P01328</Swissprot><Swissprot>P01329</Swissprot><Swissprot>P01330</Swissprot><Swissprot>P01331</Swissprot><Swissprot>P01333</Swissprot><Swissprot>P01334</Swissprot><Swissprot>P01335</Swissprot><Swissprot>P01336</Swissprot><Swissprot>P01340</Swissprot><Swissprot>P01342</Swissprot><Swissprot>P04667</Swissprot><Swissprot>P06306</Swissprot><Swissprot>P07453</Swissprot><Swissprot>P09476</Swissprot><Swissprot>P09477</Swissprot><Swissprot>P0C236</Swissprot><Swissprot>P12703</Swissprot><Swissprot>P12704</Swissprot><Swissprot>P12705</Swissprot><Swissprot>P12708</Swissprot><Swissprot>P13190</Swissprot><Swissprot>P17715</Swissprot><Swissprot>P18109</Swissprot><Swissprot>P21563</Swissprot><Swissprot>P29335</Swissprot><Swissprot>P30406</Swissprot><Swissprot>P30407</Swissprot><Swissprot>P30410</Swissprot><Swissprot>P41522</Swissprot><Swissprot>P42633</Swissprot><Swissprot>P51463</Swissprot><Swissprot>P67968</Swissprot><Swissprot>P67969</Swissprot><Swissprot>P67970</Swissprot><Swissprot>P67971</Swissprot><Swissprot>P67972</Swissprot><Swissprot>P67973</Swissprot><Swissprot>P67974</Swissprot><Swissprot>P68243</Swissprot><Swissprot>P68245</Swissprot><Swissprot>P68987</Swissprot><Swissprot>P68988</Swissprot><Swissprot>P68989</Swissprot><Swissprot>P68990</Swissprot><Swissprot>P68991</Swissprot><Swissprot>P68992</Swissprot><Swissprot>P69045</Swissprot><Swissprot>P69046</Swissprot><Swissprot>P69047</Swissprot><Swissprot>P69048</Swissprot><Swissprot>P81025</Swissprot><Swissprot>P81423</Swissprot><Swissprot>P81881</Swissprot><Swissprot>Q62587</Swissprot><Swissprot>Q6YK33</Swissprot><Swissprot>Q8HXV2</Swissprot><Swissprot>Q91XI3</Swissprot><Swissprot>Q98TA8</Swissprot><Swissprot>Q9TQY7</Swissprot><Swissprot>Q9W7R2</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=1667749" linkType="reference" linkID="1667749"&gt;1667749&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>